<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Patient Prefer Adherence</journal-id><journal-id journal-id-type="iso-abbrev">Patient Prefer Adherence</journal-id><journal-id journal-id-type="publisher-id">Patient Preference and Adherence</journal-id><journal-title-group><journal-title>Patient preference and adherence</journal-title></journal-title-group><issn pub-type="epub">1177-889X</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25214772</article-id><article-id pub-id-type="pmc">4159395</article-id><article-id pub-id-type="doi">10.2147/PPA.S66619</article-id><article-id pub-id-type="publisher-id">ppa-8-1185</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Effects of a pharmaceutical care model on medication adherence and glycemic control of people with type 2 diabetes</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chung</surname><given-names>Wen Wei</given-names></name><xref ref-type="aff" rid="af1-ppa-8-1185">1</xref><xref ref-type="aff" rid="af2-ppa-8-1185">2</xref></contrib><contrib contrib-type="author"><name><surname>Chua</surname><given-names>Siew Siang</given-names></name><xref ref-type="aff" rid="af1-ppa-8-1185">1</xref></contrib><contrib contrib-type="author"><name><surname>Lai</surname><given-names>Pauline Siew Mei</given-names></name><xref ref-type="aff" rid="af3-ppa-8-1185">3</xref></contrib><contrib contrib-type="author"><name><surname>Chan</surname><given-names>Siew Pheng</given-names></name><xref ref-type="aff" rid="af4-ppa-8-1185">4</xref><xref ref-type="corresp" rid="c1-ppa-8-1185"/></contrib></contrib-group><aff id="af1-ppa-8-1185"><label>1</label>Department of Pharmacy, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia</aff><aff id="af2-ppa-8-1185"><label>2</label>Pharmacy Department, University Malaya Medical Centre, Kuala Lumpur, Malaysia</aff><aff id="af3-ppa-8-1185"><label>3</label>Department of Primary Care Medicine, University Malaya Primary Care Research Group, Kuala Lumpur, Malaysia</aff><aff id="af4-ppa-8-1185"><label>4</label>Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia</aff><author-notes><corresp id="c1-ppa-8-1185">Correspondence: Siew Siang Chua, Department of Pharmacy, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia, Tel +60 3 7967 6688, Fax +60 3 7967 4964, Email <email>chuass@um.edu.my</email></corresp></author-notes><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>04</day><month>9</month><year>2014</year></pub-date><volume>8</volume><fpage>1185</fpage><lpage>1194</lpage><permissions><copyright-statement>&#x000a9; 2014 Chung et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution &#x02013; Non Commercial (unported, v3.0) License</copyright-statement><copyright-year>2014</copyright-year><license><license-p>The full terms of the License are available at <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.</license-p></license></permissions><abstract><sec><title>Background</title><p>Diabetes mellitus is a lifelong chronic condition that requires self-management. Lifestyle modification and adherence to antidiabetes medications are the major determinants of therapeutic success in the management of diabetes.</p></sec><sec><title>Purpose</title><p>To assess the effects of a pharmaceutical care (PC) model on medication adherence and glycemic levels of people with type 2 diabetes mellitus.</p></sec><sec><title>Patients and methods</title><p>A total of 241 people with type 2 diabetes were recruited from a major teaching hospital in Malaysia and allocated at random to the control (n=121) or intervention (n=120) groups. Participants in the intervention group received PC from an experienced pharmacist, whereas those in the control group were provided the standard pharmacy service. Medication adherence was assessed using the Malaysian Medication Adherence Scale, and glycemic levels (glycated hemoglobin values and fasting blood glucose [FBG]) of participants were obtained at baseline and after 4, 8, and 12 months.</p></sec><sec><title>Results</title><p>At baseline, there were no significant differences in demographic data, medication adherence, and glycemic levels between participants in the control and intervention groups. However, statistically significant differences in FBG and glycated hemoglobin values were observed between the control and intervention groups at months 4, 8, and 12 after the provision of PC (median FBG, 9.0 versus 7.2 mmol/L [<italic>P</italic>&#x0003c;0.001]; median glycated hemoglobin level, 9.1% versus 8.0% [<italic>P</italic>&#x0003c;0.001] at 12 months). Medication adherence was also significantly associated with the provision of PC, with a higher proportion in the intervention group than in the control group achieving it (75.0% versus 58.7%; <italic>P</italic>=0.007).</p></sec><sec><title>Conclusion</title><p>The provision of PC has positive effects on medication adherence as well as the glycemic control of people with type 2 diabetes. Therefore, the PC model used in this study should be duplicated in other health care settings for the benefit of more patients with type 2 diabetes.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>pharmaceutical care</kwd><kwd>medication adherence</kwd><kwd>glycemic control</kwd><kwd>type 2 diabetes mellitus</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>The International Diabetes Foundation predicted that by 2025, the Southeast Asia Region would have the highest prevalence of diabetes.<xref rid="b1-ppa-8-1185" ref-type="bibr">1</xref>,<xref rid="b2-ppa-8-1185" ref-type="bibr">2</xref> In Malaysia, the Third National Health Morbidity Survey reported a drastic increase in the prevalence of diabetes, from 8.3% to 14.9%, among Malaysians aged 30 years and older within a 10-year period (1996&#x02013;2006).<xref rid="b3-ppa-8-1185" ref-type="bibr">3</xref> The World Health Organization estimated that by 2030, Malaysia would have a total of 2.48 million individuals diagnosed with diabetes;<xref rid="b3-ppa-8-1185" ref-type="bibr">3</xref> however, this figure has already been surpassed, as in 2011, 2.6 million Malaysians had been diagnosed with diabetes.<xref rid="b2-ppa-8-1185" ref-type="bibr">2</xref>,<xref rid="b4-ppa-8-1185" ref-type="bibr">4</xref> This increase in diabetes is a major concern, as the morbidity of people with diabetes is 11 times higher than the general population.<xref rid="b5-ppa-8-1185" ref-type="bibr">5</xref></p><p>Diabetes mellitus is a lifelong chronic condition that requires self-management by individuals. Lifestyle modification and adherence to antidiabetes medications are the major determinants of therapeutic success in the management of diabetes.<xref rid="b6-ppa-8-1185" ref-type="bibr">6</xref> Studies demonstrate that poor glycemic control results in the development of long-term complications and was also associated with disease progression, hospitalization, premature disability, and mortality.<xref rid="b7-ppa-8-1185" ref-type="bibr">7</xref>&#x02013;<xref rid="b9-ppa-8-1185" ref-type="bibr">9</xref> A study conducted in Malaysia found that 58% of people with diabetes had neuropathy, 53% had retinopathy, 8.6% had cardiovascular diseases, 5.6% had stroke, and 1.9% had amputation.<xref rid="b10-ppa-8-1185" ref-type="bibr">10</xref></p><p>In addition, other studies have found a significant association between adherence to antidiabetes medications and glycemic control.<xref rid="b11-ppa-8-1185" ref-type="bibr">11</xref>&#x02013;<xref rid="b17-ppa-8-1185" ref-type="bibr">17</xref> A study conducted in Malaysia found that 41.7% of people with diabetes did not adhere to their antidiabetes medications and that the odds of achieving glycemic control were two times higher among those who adhered to their antidiabetes medications compared with those who did not.<xref rid="b18-ppa-8-1185" ref-type="bibr">18</xref> Another study also concluded that those who were nonadherent to their medications had significantly higher levels of fasting blood glucose.<xref rid="b19-ppa-8-1185" ref-type="bibr">19</xref>,<xref rid="b20-ppa-8-1185" ref-type="bibr">20</xref></p><p>The roles of pharmacists within the health care system today have evolved from a product-centered approach to patient-centered care, which means the refocusing of time and energy on professional responsibilities.<xref rid="b20-ppa-8-1185" ref-type="bibr">20</xref>&#x02013;<xref rid="b23-ppa-8-1185" ref-type="bibr">23</xref> Therefore, the fundamental goal of pharmacy practice today is to provide pharmaceutical care (PC).<xref rid="b24-ppa-8-1185" ref-type="bibr">24</xref> PC is the responsible provision of drug therapy via collaboration of a clinical pharmacist with the patient, as well as other members of the health care team, in designing, implementing, and monitoring a therapeutic plan that will produce specific outcomes. This includes identifying potential and actual drug-related problems, resolving current drug-related problems, and preventing future drug-related problems.<xref rid="b25-ppa-8-1185" ref-type="bibr">25</xref></p><p>Studies on the effects of PC in the management of diabetes observed a statistically significant reduction in glycated hemoglobin (HbA<sub>1c</sub>) levels in the intervention group.<xref rid="b11-ppa-8-1185" ref-type="bibr">11</xref>,<xref rid="b26-ppa-8-1185" ref-type="bibr">26</xref>&#x02013;<xref rid="b34-ppa-8-1185" ref-type="bibr">34</xref> However, most of the studies in the literature were conducted in countries such as the United States, the United Kingdom, and Australia.<xref rid="b11-ppa-8-1185" ref-type="bibr">11</xref>,<xref rid="b26-ppa-8-1185" ref-type="bibr">26</xref>&#x02013;<xref rid="b34-ppa-8-1185" ref-type="bibr">34</xref></p><p>The hypothesis is that although the provision of PC in Malaysia has increased gradually over the last 2 decades, a majority of pharmacists in Malaysia are still not intensively involved in patient care, and hence, such service is deemed to have a greater effect in Malaysia than in the developed countries, where the roles of pharmacists in patient care are already well-established. In addition, such studies are still scarce in developing countries such as Malaysia, and thus far, there is only one qualitative study that has been published with regard to PC.<xref rid="b35-ppa-8-1185" ref-type="bibr">35</xref> Therefore, the present study is warranted to investigate the effects of a PC model on medication adherence and glycemic levels of people with type 2 diabetes (T2DM).</p></sec><sec sec-type="methods"><title>Methods</title><p>This is a prospective randomized controlled trial. The study was approved by the Medical Ethics Committee of the major teaching hospital involved in the study (MEC 757.112). Written, informed consent was obtained from all the participants on recruitment into this study.</p><sec sec-type="subjects"><title>Participants</title><p>People who had been diagnosed with T2DM who were aged 21 years and older but were younger than 75 years, were taking at least one antidiabetes medication, were able to communicate in English, and had an HbA<sub>1c</sub> level of 8% and above, could be included in this study. Any person with T2DM who visited the diabetes clinic of a major teaching hospital during the recruitment period and who fulfilled the inclusion criteria was requested to participate in this study. Participants&#x02019; fasting blood glucose (FBG) levels and HbA<sub>1c</sub> values were obtained from their medical records.</p><p>Participants&#x02019; demographic and medical characteristics were collected via face-to-face interview and confirmed with participants&#x02019; medical records. Medication adherence of participants was assessed using the validated Malaysian Medication Adherence Scale (MALMAS).<xref rid="b36-ppa-8-1185" ref-type="bibr">36</xref> MALMAS was developed and scored according to the Morisky Medication Adherence scale,<xref rid="b37-ppa-8-1185" ref-type="bibr">37</xref>,<xref rid="b38-ppa-8-1185" ref-type="bibr">38</xref> on which the total score ranged from 0&#x02013;8. Medication adherence was classified into three levels on the basis of the total scores obtained: low adherence (total score, &#x0003c;6), medium adherence (total score, 6&#x02013;7.9), and high adherence (total score, 8). In addition, medication adherence was classified into medication adherence (total score, 6&#x02013;8) and nonadherence (total score, &#x0003c;6).<xref rid="b36-ppa-8-1185" ref-type="bibr">36</xref></p></sec><sec><title>Procedure</title><p>Participants were allocated at random to the control or intervention groups. Participants in the intervention group received PC from a pharmacist, whereas those in the control group were provided standard pharmacy services, which consisted of dispensing the medications and providing brief instructions on how to take them. A pharmacist reviewed the medications of those in the intervention group and tried to resolve any drug-related problems encountered by the participants. In addition, participants in the intervention group were educated on diabetes, hypertension, and hyperlipidemia, as well as all aspects of their medications, with an emphasis on the importance of medication adherence. The intervention group was also given and taught how to use a pill box and a blood glucose meter to conduct self-monitoring of blood glucose at home and to record their readings. Participants in the intervention group received monthly follow-up telephone calls to help participants resolve any pharmaceutical care issues or drug-related problems.</p><p>All participants from both control and intervention groups were asked to return to the pharmacy for their next visit, which should preferably be about 3&#x02013;4 months from the date of recruitment. Participants from both groups had their blood samples taken by a nurse and tested for FBG and HbA<sub>1c</sub> levels by a certified clinical laboratory of the teaching hospital about a week before their next appointment for the study. Participants from the intervention group were counseled by a pharmacist regarding their blood glucose levels. If the participants did not have their blood glucose levels under control, then more stringent measures would be recommended after discussion with the participants&#x02019; clinicians. Data were collected at recruitment (baseline) and then at 4, 8, and 12 months after recruitment. All interventions were conducted in accordance with a PC counseling and education checklist. Each intervention took approximately an hour at baseline, whereas subsequent visits took approximately half an hour for the pharmacist to provide counseling and education to each intervention participant.</p><p>In line with the UK Prospective Diabetes Study, a 1% reduction in HbA<sub>1c</sub> level reduces the risk for myocardial infarction by 14%, that for microvascular complications by 37%, and that for diabetes-related deaths by 21%.<xref rid="b39-ppa-8-1185" ref-type="bibr">39</xref>,<xref rid="b40-ppa-8-1185" ref-type="bibr">40</xref> Therefore, the present study would be deemed successful if a reduction of at least 1% in HbA<sub>1c</sub> value could be achieved.</p></sec><sec sec-type="methods"><title>Statistical analysis</title><p>All data were analyzed using PASW Statistics for Windows, version 18 (SPSS Inc., Chicago, IL, USA). Associations between categorical variables were analyzed using Pearson chi-square tests, whereas differences in clinical outcome measures (continuous variables) between the control and intervention groups were evaluated using independent <italic>t</italic>-test or Mann&#x02013;Whitney <italic>U</italic>-test. Differences between baseline and endpoint outcome measures were determined using the paired <italic>t</italic>-test or Wilcoxon signed-rank test. The Generalized Estimating Equations (GEE) was used to analyze the predictors of the study outcomes, HbA<sub>1c</sub>, and medication adherence. Various parameters (such as participant&#x02019;s age, sex, ethnic group, education level, working status, income group, marital status, levels of exercise, body mass index [BMI] status, duration of diagnosis with diabetes, number of concurrent diseases, total number of prescribed medications, and whether in the control or intervention group) that may be associated with the study outcomes were included in the GEE analysis. Any <italic>P</italic>-value less than 0.05 was considered statistically significant.</p></sec></sec><sec sec-type="results"><title>Results</title><p>A total of 241 participants were recruited for this study. The demographic and medical data of the participants are as shown in <xref ref-type="table" rid="t1-ppa-8-1185">Table 1</xref>. The thresholds for income groups were classified according to a household income survey conducted in Malaysia.<xref rid="b41-ppa-8-1185" ref-type="bibr">41</xref> In this survey, the middle-class income group was considered as from RM1,001 to RM5,000 per month. Therefore, in the present study, the middle-class group was divided into a lower middle-class income group (RM1,001&#x02013;RM3,000) and an upper middle-class income group (RM3,001&#x02013;RM5,000). The BMI of participants was categorized using international thresholds: healthy, 18.5&#x02013;24.9 kg/m<sup>2</sup>; overweight, 25&#x02013;29.9 kg/m<sup>2</sup>; and obese, 30 kg/m<sup>2</sup> and above.<xref rid="b42-ppa-8-1185" ref-type="bibr">42</xref> The BMI of both control and intervention groups also did not show any significant difference at baseline. <xref ref-type="table" rid="t1-ppa-8-1185">Table 1</xref> shows a much higher proportion of participants with diploma and tertiary education in the intervention group compared with in the control group (42.5% vs 27.2%), although it was not statistically significant. Using the GEE analysis, it was found that education levels were not significantly related to medication adherence or HbA<sub>1c</sub>.</p><p>Medication adherence of participants was assessed using the MALMAS (<xref ref-type="table" rid="t2-ppa-8-1185">Table 2</xref>). Glycemic levels of participants are represented by FBG and HbA<sub>1c</sub> (<xref ref-type="fig" rid="f1-ppa-8-1185">Figures 1</xref> and <xref ref-type="fig" rid="f2-ppa-8-1185">2</xref>). Using the Kolmogorov&#x02013;Smirnov test, the <italic>P</italic>-values for all domains were less than 0.001, which implied that the data did not fulfil the normal distribution criteria. At baseline, there were no significant differences in demographic data and other characteristics, medication adherence, or glycemic levels between participants in the control and intervention groups (<xref ref-type="table" rid="t1-ppa-8-1185">Tables 1</xref> and <xref ref-type="table" rid="t2-ppa-8-1185">2</xref>; <xref ref-type="fig" rid="f1-ppa-8-1185">Figures 1</xref> and <xref ref-type="fig" rid="f2-ppa-8-1185">2</xref>).</p><sec><title>Medication adherence</title><p>Whether medication adherence was categorized into three (high, medium, and low adherence) or two (high or medium adherence, which are considered as adherent to medication, and low adherence, which is considered as nonadherence to medication) levels,<xref rid="b36-ppa-8-1185" ref-type="bibr">36</xref> there were significant associations between the levels of adherence and the provision of PC at months 4, 8, and 12 (<xref ref-type="table" rid="t2-ppa-8-1185">Tables 2</xref> and <xref ref-type="table" rid="t3-ppa-8-1185">3</xref>).</p></sec><sec><title>Outcomes of glycemic levels (FBG and HbA<sub>1c</sub>)</title><p>Statistically significant differences in FBG and HbA<sub>1c</sub> were observed between the control and intervention groups at 4 months after intervention, and these continued until the end of the study period (12 months; <xref ref-type="fig" rid="f1-ppa-8-1185">Figures 1</xref> and <xref ref-type="fig" rid="f2-ppa-8-1185">2</xref>). In addition, FBG and HbA<sub>1c</sub> showed a statistically significant reduction from recruitment until the end of the study period (12 months after the provision of PC) for the intervention group, whereas the control group did not have any significant changes (<xref ref-type="table" rid="t4-ppa-8-1185">Table 4</xref>). At the end of the 12-month study period, there were significant differences between the percentage of the control and intervention groups who achieved FBG less than 6.2 mmol/L and HbA<sub>1c</sub> levels less than 8% (FBG, 18.2% versus 31.7% [chi-square, 5.859; <italic>P</italic>=0.015]; HbA<sub>1c</sub>, 22.3% versus 47.5% [chi-square, 16.831; <italic>P</italic>&#x0003c;0.001], respectively).</p><p>After accounting for confounding factors and interactions, the GEE analysis showed that the PC intervention was significantly related to a reduction in HbA<sub>1c</sub> (Wald chi-square, 9.518; regression coefficient, B, &#x02212;0.486 [95% confidence interval (CI), &#x02212;0.177 to &#x02212;0.795]; <italic>P</italic>=0.002) and an increase in medication adherence (Wald chi-square, 6.694; odds ratio, 1.903; 95% CI, 1.169&#x02013;3.099; <italic>P</italic>=0.010).</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>The findings of the study show that the PC model used has a positive effect on medication adherence and on the glycemic control (FBG and HbA<sub>1c</sub>) of people with T2DM. There was no significant difference at baseline in terms of demographic and medical data between the control and intervention groups.</p><p>The present study has about 10% more female than male participants (<xref ref-type="table" rid="t1-ppa-8-1185">Table 1</xref>), but the Malaysian Third National Health Morbidity Survey and the International Diabetes Federation have shown that the prevalence of T2DM in males was comparable with that in females.<xref rid="b1-ppa-8-1185" ref-type="bibr">1</xref>,<xref rid="b2-ppa-8-1185" ref-type="bibr">2</xref>,<xref rid="b43-ppa-8-1185" ref-type="bibr">43</xref> The higher proportion of female participants may be because females with T2DM are more willing to participate in the study than males, as they are more likely to be nonworking housewives. The mean age of participants in this study is comparable with that in a previous study (59 versus 57.5 years old).<xref rid="b44-ppa-8-1185" ref-type="bibr">44</xref> The proportions of participants who are of Indian origin in this study is considered very high (33.5%), as this ethnic group in Malaysia only constitutes about 10% of its population. This corresponds with other studies that found that the prevalence of T2DM is highest among people of Indian origin.<xref rid="b2-ppa-8-1185" ref-type="bibr">2</xref>,<xref rid="b43-ppa-8-1185" ref-type="bibr">43</xref></p><p>The demographic and metabolic characteristics of the participants in this study are also similar to those obtained in the DiabCare Malaysia 2008 study.<xref rid="b43-ppa-8-1185" ref-type="bibr">43</xref> Approximately 25% of participants in the present study were overweight, whereas more than 50% were obese. This percentage is also comparable with that obtained from the DiabCare Malaysia 2008 study (mean BMI, 29 kg/m<sup>2</sup> versus 27.8 kg/m<sup>2</sup>).<xref rid="b43-ppa-8-1185" ref-type="bibr">43</xref>,<xref rid="b44-ppa-8-1185" ref-type="bibr">44</xref> The growing prevalence of obesity and overweight cases is closely linked to the upsurge in the number of diabetes cases. Approximately 90% of T2DM cases are attributed to being overweight.<xref rid="b43-ppa-8-1185" ref-type="bibr">43</xref>,<xref rid="b44-ppa-8-1185" ref-type="bibr">44</xref> Therefore, counseling on lifestyle modification is essential in the management of diabetes.</p><p>At 4, 8, and 12 months after the provision of PC to the intervention group, there was significant association between the prevalence of medication adherence and whether the participants were in the intervention or control group (<xref ref-type="table" rid="t2-ppa-8-1185">Tables 2</xref> and <xref ref-type="table" rid="t3-ppa-8-1185">3</xref>). This implies that the provision of PC to the intervention group has improved medication adherence significantly.</p><p>The relationships among participants, health care providers, and social support are fundamental interpersonal factors that are closely related to medication adherence.<xref rid="b3-ppa-8-1185" ref-type="bibr">3</xref> In the present study, several consultations with the pharmacist enabled the development and establishment of a better patient&#x02013;pharmacist professional relationship. These consultations increased the trust of the participants and hence may have contributed to improved medication adherence. Other studies also report that good communication between participants and health care providers leads to favorable and improved medication adherence among people with T2DM.<xref rid="b45-ppa-8-1185" ref-type="bibr">45</xref></p><p>Participants in this study also had to manage complicated drug regimens, as more than 60% of the participants were receiving 6&#x02013;10 medications. This increases the risk for an adverse event and/or a potential adherence issue. Therefore, continual assessment and surveillance by a pharmacist to identify and help these people resolve their drug-related problems is essential for the successful management of diabetes.</p><p>Significant improvements in glycemic control were observed at 4 months after implementing the PC model, and this was sustained until the end of the study. These findings are similar to those of other studies conducted in other countries.<xref rid="b46-ppa-8-1185" ref-type="bibr">46</xref>&#x02013;<xref rid="b49-ppa-8-1185" ref-type="bibr">49</xref> This shows that the PC model used in this study was effective in improving the medication adherence and glycemic levels of patients with T2DM.</p><p>Nonetheless, the average mean values of FBG and HbA<sub>1c</sub> of the participants were still above the recommended target range at the end of the study period. This may be because of the high baseline values during the recruitment period (mean of control: FBG, 9.2 mmol/L; HbA<sub>1c</sub>, 9.5%; intervention: FBG, 9.4 mmol/L; HbA<sub>1c</sub>, 9.6%). However, the proportion of participants in the intervention group who achieved HbA<sub>1c</sub> levels less than 8% at the end of the study period was significantly higher than that of the control group. In addition, the results showed that the intervention participants achieved a mean reduction in HbA<sub>1c</sub> of 1.4% (going from 9.6%&#x02013;8.2% at the end of the study period). Therefore, this reduction is considered clinically significant, and the PC model is deemed to be successful.</p><p>For each 10% increase in adherence, HbA<sub>1c</sub> decreased significantly by 0.14%&#x02013;0.16%.<xref rid="b50-ppa-8-1185" ref-type="bibr">50</xref> However, in the present study, HbA<sub>1c</sub> improved by 1.4%, whereas the adherence levels improved by 5%. Nonetheless, this indicates the importance of emphasizing medication adherence as part of a diabetes management program.</p><p>The GEE model shows that the PC intervention has a significant positive effect on HbA<sub>1c</sub> values and on the medication adherence of people with T2DM. The odds of the intervention participants being adherent to their medications were almost double the odds for those who did not receive pharmaceutical care. This further confirms the importance of providing pharmaceutical care services as a component of diabetes management.</p><sec sec-type="methods"><title>Limitations of the study</title><p>One of the limitations of this study was that it was conducted in English only. However, Malaysia is a multiracial society with three main ethnic groups: Malays, Chinese, and Indians. Therefore, the results may not be representative of T2DM patients who cannot communicate in English.</p><p>In addition, the study was conducted only in a single hospital, and hence the results could not be generalized to T2DM patients in other hospitals and in community pharmacy settings, although the demographic data of the participants corresponds with those of other studies. There may also be cross-contamination between participants in the control and intervention groups that could not be avoided, as they were attending the same clinic. Control participants may have discussed the study with the intervention participants and obtained some information regarding their disease conditions and medications. Therefore, the effects of the PC intervention may have been diluted. In addition, the implementation of this PC model on a wider scale may be limited by the health care infrastructure, as well as possibly cost and patients&#x02019; access to health care facilities.</p><p>The participants were followed-up for only one year due to limited study time frame, which may not be adequate to detect long-term diabetes complications, and hence the long-term benefits of the PC model used in this study could not be determined.</p></sec></sec><sec><title>Conclusion</title><p>The collaborative efforts between pharmacists and other health care professionals through the provision of PC, as demonstrated in this study, has positive effects on medication adherence and glycemic levels of people with T2DM. Therefore, the PC model used in this study should be duplicated in other health care settings for the benefit of more people with T2DM. Further studies can be conducted to evaluate the long-term effects of PC, as well as the cost-effectiveness of such services.</p></sec></body><back><ack><title>Acknowledgments</title><p>We acknowledge the University of Malaya for funding this project under grant PG 138-2012B. We also express our appreciation to Samihah Mat Junoh for her assistance in recruiting participants and data collection. We also thank Dr David Wu from Monash University Sunway Campus for his advice and assistance on statistical analysis, as well as Christopher Wilcox from the University of South Florida for his assistance in editing this manuscript. We are very grateful to all the study participants for their full cooperation during the data collection period and for their willingness to be in the study. In addition, we acknowledge the cooperation and assistance of all the staff in the Pharmacy Department and the Diabetes Clinic of the University Malaya Medical Centre.</p></ack><fn-group><fn><p><bold>Author contributions</bold></p><p>WWC organized the study, collected the data, contributed to the discussion, and drafted the manuscript. SSC was involved in the design of the study, contributed to the discussion, and reviewed and edited the manuscript. PSML contributed to the discussion and reviewed and edited the manuscript. SPC provided clinical advice, contributed to the discussion, and reviewed and edited the manuscript. All authors checked the final version of the manuscript before submission.</p></fn></fn-group><fn-group><fn><p><bold>Disclosure</bold></p><p>The authors report no conflicts of interest in this work.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-ppa-8-1185"><label>1</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><source>Adherence to Long-term Therapies: Evidence for Action</source><publisher-loc>Geneva</publisher-loc><publisher-name>World Health Organization</publisher-name><year>2003</year><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/chp/knowledge/publications/adherence_report/en/">http://www.who.int/chp/knowledge/publications/adherence_report/en/</ext-link></comment><date-in-citation>Accessed June 24, 2013</date-in-citation></element-citation></ref><ref id="b2-ppa-8-1185"><label>2</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>International Diabetes Federation</collab></person-group><source>IDF Diabetes Atlas</source><edition>6th ed</edition><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.idf.org/sites/default/files/EN_6E_Atlas_Full_0.pdf">http://www.idf.org/sites/default/files/EN_6E_Atlas_Full_0.pdf</ext-link></comment><date-in-citation>Accessed: June 15, 2013</date-in-citation></element-citation></ref><ref id="b3-ppa-8-1185"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Letchuman</surname><given-names>GR</given-names></name><name><surname>Wan Nazaimoon</surname><given-names>WM</given-names></name><name><surname>Wan Mohamad</surname><given-names>WB</given-names></name><etal/></person-group><article-title>Prevalence of diabetes in the Malaysian National Health Morbidity Survey III 2006</article-title><source>Med J Malaysia</source><year>2010</year><volume>65</volume><issue>3</issue><fpage>173</fpage><lpage>179</lpage><comment>Available from <ext-link ext-link-type="uri" xlink:href="http://www.e-mjm.org/2010/v65n3/Diabetes.pdf">http://www.e-mjm.org/2010/v65n3/Diabetes.pdf</ext-link>. Accessed August 11, 2014.</comment><pub-id pub-id-type="pmid">21939163</pub-id></element-citation></ref><ref id="b4-ppa-8-1185"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mustapha</surname><given-names>F</given-names></name><name><surname>Omar</surname><given-names>Z</given-names></name><name><surname>Mihat</surname><given-names>O</given-names></name><etal/></person-group><article-title>Addressing non-communicable diseases in Malaysia: an integrative process of systems and community</article-title><source>BMC Public Health</source><year>2014</year><volume>14</volume><issue>Suppl 2</issue><fpage>S4</fpage><pub-id pub-id-type="pmid">25080846</pub-id></element-citation></ref><ref id="b5-ppa-8-1185"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clifford</surname><given-names>RM</given-names></name><name><surname>Davis</surname><given-names>WA</given-names></name><name><surname>Batty</surname><given-names>KT</given-names></name><name><surname>Davis</surname><given-names>TM</given-names></name><collab>Fremantle Diabetes Study</collab></person-group><article-title>Effect of a pharmaceutical care program on vascular risk factors in type 2 diabetes: the Fremantle Diabetes Study</article-title><source>Diabetes Care</source><year>2005</year><volume>28</volume><issue>4</issue><fpage>771</fpage><lpage>776</lpage><pub-id pub-id-type="pmid">15793171</pub-id></element-citation></ref><ref id="b6-ppa-8-1185"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scain</surname><given-names>SF</given-names></name><name><surname>Friedman</surname><given-names>R</given-names></name><name><surname>Gross</surname><given-names>JL</given-names></name></person-group><article-title>A structured educational program improves metabolic control in patients with type 2 diabetes: a randomized controlled trial</article-title><source>Diabetes Educ</source><year>2009</year><volume>35</volume><issue>4</issue><fpage>603</fpage><lpage>611</lpage><pub-id pub-id-type="pmid">19451553</pub-id></element-citation></ref><ref id="b7-ppa-8-1185"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>American Diabetes Association</collab></person-group><article-title>Diagnosis and classification of diabetes mellitus</article-title><source>Diabetes Care</source><year>2013</year><volume>36</volume><issue>Suppl 1</issue><fpage>S67</fpage><lpage>S74</lpage><pub-id pub-id-type="pmid">23264425</pub-id></element-citation></ref><ref id="b8-ppa-8-1185"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pladevall</surname><given-names>M</given-names></name><name><surname>Williams</surname><given-names>LK</given-names></name><name><surname>Potts</surname><given-names>LA</given-names></name><name><surname>Divine</surname><given-names>G</given-names></name><name><surname>Xi</surname><given-names>H</given-names></name><name><surname>Lafata</surname><given-names>JE</given-names></name></person-group><article-title>Clinical outcomes and adherence to medications measured by claims data in patients with diabetes</article-title><source>Diabetes Care</source><year>2004</year><volume>27</volume><issue>12</issue><fpage>2800</fpage><lpage>2805</lpage><pub-id pub-id-type="pmid">15562188</pub-id></element-citation></ref><ref id="b9-ppa-8-1185"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>UK Prospective Diabetes Study Group</collab></person-group><article-title>Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38</article-title><source>BMJ</source><year>1998</year><volume>317</volume><issue>7160</issue><fpage>703</fpage><lpage>713</lpage><pub-id pub-id-type="pmid">9732337</pub-id></element-citation></ref><ref id="b10-ppa-8-1185"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaini</surname><given-names>A</given-names></name></person-group><article-title>Where is Malaysia in the midst of the Asian epidemic of diabetes mellitus?</article-title><source>Diabetes Res Clin Pract</source><year>2000</year><volume>50</volume><issue>Suppl 2</issue><fpage>S23</fpage><lpage>S28</lpage><pub-id pub-id-type="pmid">11024580</pub-id></element-citation></ref><ref id="b11-ppa-8-1185"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krass</surname><given-names>I</given-names></name><name><surname>Taylor</surname><given-names>SJ</given-names></name><name><surname>Smith</surname><given-names>C</given-names></name><name><surname>A</surname><given-names>CL</given-names></name></person-group><article-title>Impact on medication use and adherence of Australian pharmacists&#x02019; diabetes care services</article-title><source>J Am Pharm Assoc</source><year>2003</year><volume>45</volume><issue>1</issue><fpage>33</fpage><lpage>40</lpage></element-citation></ref><ref id="b12-ppa-8-1185"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krass</surname><given-names>I</given-names></name><name><surname>Hebing</surname><given-names>R</given-names></name><name><surname>Mitchell</surname><given-names>B</given-names></name><etal/></person-group><article-title>Diabetes management in an Australian primary care population</article-title><source>J Clin Pharm Ther</source><year>2011</year><volume>36</volume><issue>6</issue><fpage>664</fpage><lpage>672</lpage><pub-id pub-id-type="pmid">21355875</pub-id></element-citation></ref><ref id="b13-ppa-8-1185"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>LR</given-names></name><name><surname>Williams</surname><given-names>SL</given-names></name><name><surname>Haskard</surname><given-names>KB</given-names></name><name><surname>Dimatteo</surname><given-names>MR</given-names></name></person-group><article-title>The challenge of patient adherence</article-title><source>Ther Clin Risk Manag</source><year>2005</year><volume>1</volume><issue>3</issue><fpage>189</fpage><lpage>199</lpage><pub-id pub-id-type="pmid">18360559</pub-id></element-citation></ref><ref id="b14-ppa-8-1185"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehuys</surname><given-names>E</given-names></name><name><surname>Van Bortel</surname><given-names>L</given-names></name><name><surname>De Bolle</surname><given-names>L</given-names></name><etal/></person-group><article-title>Effectiveness of a community pharmacist intervention in diabetes care: a randomized controlled trial</article-title><source>J Clin Pharm Ther</source><year>2011</year><volume>36</volume><issue>5</issue><fpage>602</fpage><lpage>613</lpage><pub-id pub-id-type="pmid">21143256</pub-id></element-citation></ref><ref id="b15-ppa-8-1185"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nichols-English</surname><given-names>G</given-names></name><name><surname>Poirier</surname><given-names>S</given-names></name></person-group><article-title>Optimizing adherence to pharmaceutical care plans</article-title><source>J Am Pharm Assoc (Wash)</source><year>2000</year><volume>40</volume><issue>4</issue><fpage>475</fpage><lpage>485</lpage><pub-id pub-id-type="pmid">10932456</pub-id></element-citation></ref><ref id="b16-ppa-8-1185"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horswell</surname><given-names>RL</given-names></name><name><surname>Wascom</surname><given-names>CK</given-names></name><name><surname>Cerise</surname><given-names>FP</given-names></name><etal/></person-group><article-title>Diabetes mellitus medication assistance program: relationship of effectiveness to adherence</article-title><source>J Health Care Poor Underserved</source><year>2008</year><volume>19</volume><issue>3</issue><fpage>677</fpage><lpage>686</lpage><pub-id pub-id-type="pmid">18677064</pub-id></element-citation></ref><ref id="b17-ppa-8-1185"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmad</surname><given-names>NS</given-names></name><name><surname>Ramli</surname><given-names>A</given-names></name><name><surname>Islahudin</surname><given-names>F</given-names></name><name><surname>Paraidathathu</surname><given-names>T</given-names></name></person-group><article-title>Medication adherence in patients with type 2 diabetes mellitus treated at primary health clinics in Malaysia</article-title><source>Patient Prefer Adherence</source><year>2013</year><volume>7</volume><fpage>525</fpage><lpage>530</lpage><pub-id pub-id-type="pmid">23814461</pub-id></element-citation></ref><ref id="b18-ppa-8-1185"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chua</surname><given-names>SS</given-names></name><name><surname>Chan</surname><given-names>SP</given-names></name></person-group><article-title>Medication adherence and achievement of glycaemic targets in ambulatory type 2 diabetic patients</article-title><source>J Appl Pharm Sci</source><year>2011</year><volume>1</volume><issue>4</issue><fpage>55</fpage><lpage>59</lpage><comment>Available from <ext-link ext-link-type="uri" xlink:href="http://www.japsonline.com/admin/php/uploads/60_pdf.pdf">http://www.japsonline.com/admin/php/uploads/60_pdf.pdf</ext-link>. Accessed August 11, 2014.</comment></element-citation></ref><ref id="b19-ppa-8-1185"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>MY</given-names></name><name><surname>Magarey</surname><given-names>J</given-names></name></person-group><article-title>Self-care practices of Malaysian adults with diabetes and sub-optimal glycaemic control</article-title><source>Patient Educ Couns</source><year>2008</year><volume>72</volume><issue>2</issue><fpage>252</fpage><lpage>267</lpage><pub-id pub-id-type="pmid">18467068</pub-id></element-citation></ref><ref id="b20-ppa-8-1185"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grant</surname><given-names>R</given-names></name><name><surname>Adams</surname><given-names>AS</given-names></name><name><surname>Trinacty</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Relationship between patient medication adherence and subsequent clinical inertia in type 2 diabetes glycemic management</article-title><source>Diabetes Care</source><year>2007</year><volume>30</volume><issue>4</issue><fpage>807</fpage><lpage>812</lpage><pub-id pub-id-type="pmid">17259469</pub-id></element-citation></ref><ref id="b21-ppa-8-1185"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sisson</surname><given-names>E</given-names></name><name><surname>Kuhn</surname><given-names>C</given-names></name></person-group><article-title>Pharmacist roles in the management of patients with type 2 diabetes</article-title><source>J Am Pharm Assoc (2003)</source><year>2009</year><volume>49</volume><issue>(0)(Suppl 1)</issue><fpage>S41</fpage><lpage>S45</lpage><pub-id pub-id-type="pmid">19801364</pub-id></element-citation></ref><ref id="b22-ppa-8-1185"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schapansky</surname><given-names>LM</given-names></name><name><surname>Johnson</surname><given-names>JA</given-names></name></person-group><article-title>Pharmacists&#x02019; attitudes toward diabetes</article-title><source>J Am Pharm Assoc (Wash)</source><year>2000</year><volume>40</volume><issue>3</issue><fpage>371</fpage><lpage>377</lpage><pub-id pub-id-type="pmid">10853538</pub-id></element-citation></ref><ref id="b23-ppa-8-1185"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szumita</surname><given-names>PM</given-names></name></person-group><article-title>The hospital pharmacist: an integral part of the hyperglycaemic management team</article-title><source>J Clin Pharm Ther</source><year>2009</year><volume>34</volume><issue>6</issue><fpage>613</fpage><lpage>621</lpage><pub-id pub-id-type="pmid">20175794</pub-id></element-citation></ref><ref id="b24-ppa-8-1185"><label>24</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>P</given-names></name></person-group><article-title>Automation and the Future Practice of Pharmacy &#x02013; Changing the Focus of Pharmacy</article-title><person-group person-group-type="editor"><name><surname>Wilson</surname><given-names>AL</given-names></name></person-group><source>Issues in Pharmacy Practice Management United States of America</source><publisher-loc>Gaithersburg, MD</publisher-loc><publisher-name>Aspen Publishers, Inc</publisher-name><year>1997</year><fpage>79</fpage><lpage>91</lpage></element-citation></ref><ref id="b25-ppa-8-1185"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hepler</surname><given-names>CD</given-names></name><name><surname>Strand</surname><given-names>LM</given-names></name></person-group><article-title>Opportunities and responsibilities in pharmaceutical care</article-title><source>Am J Hosp Pharm</source><year>1990</year><volume>47</volume><issue>3</issue><fpage>533</fpage><lpage>543</lpage><pub-id pub-id-type="pmid">2316538</pub-id></element-citation></ref><ref id="b26-ppa-8-1185"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gold</surname><given-names>R</given-names></name><name><surname>Yu</surname><given-names>K</given-names></name><name><surname>Liang</surname><given-names>L-J</given-names></name><etal/></person-group><article-title>Synchronous provider visit and self-management education improves glycemic control in Hispanic patients with long-standing type 2 diabetes</article-title><source>Diabetes Educ</source><year>2008</year><volume>34</volume><issue>6</issue><fpage>990</fpage><lpage>995</lpage><pub-id pub-id-type="pmid">18849465</pub-id></element-citation></ref><ref id="b27-ppa-8-1185"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howteerakul</surname><given-names>N</given-names></name><name><surname>Suwannapong</surname><given-names>N</given-names></name><name><surname>Rittichu</surname><given-names>C</given-names></name><name><surname>Rawdaree</surname><given-names>P</given-names></name></person-group><article-title>Adherence to regimens and glycemic control of patients with type 2 diabetes attending a tertiary hospital clinic</article-title><source>Asia Pac J Public Health</source><year>2007</year><volume>19</volume><issue>1</issue><fpage>43</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">17784659</pub-id></element-citation></ref><ref id="b28-ppa-8-1185"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaber</surname><given-names>LA</given-names></name><name><surname>Halapy</surname><given-names>H</given-names></name><name><surname>Fernet</surname><given-names>M</given-names></name><name><surname>Tummalapalli</surname><given-names>S</given-names></name><name><surname>Diwakaran</surname><given-names>H</given-names></name></person-group><article-title>Evaluation of a pharmaceutical care model on diabetes management</article-title><source>Ann Pharmacother</source><year>1996</year><volume>30</volume><issue>3</issue><fpage>238</fpage><lpage>243</lpage><pub-id pub-id-type="pmid">8833557</pub-id></element-citation></ref><ref id="b29-ppa-8-1185"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>RK</given-names></name></person-group><article-title>Role of the pharmacist in diabetes management</article-title><source>Am J Health Syst Pharm</source><year>2002</year><volume>59</volume><issue>Suppl 9</issue><fpage>S18</fpage><lpage>S21</lpage><pub-id pub-id-type="pmid">12489383</pub-id></element-citation></ref><ref id="b30-ppa-8-1185"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>MD</given-names></name><name><surname>Young</surname><given-names>J</given-names></name><name><surname>Hoke</surname><given-names>S</given-names></name><etal/></person-group><article-title>Pharmacist intervention to improve medication adherence in heart failure: a randomized trial</article-title><source>Ann Intern Med</source><year>2007</year><volume>146</volume><issue>10</issue><fpage>714</fpage><lpage>725</lpage><pub-id pub-id-type="pmid">17502632</pub-id></element-citation></ref><ref id="b31-ppa-8-1185"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>JC</given-names></name><name><surname>Conner</surname><given-names>DA</given-names></name><name><surname>Venohr</surname><given-names>I</given-names></name><etal/></person-group><article-title>Effectiveness of a group outpatient visit model for chronically ill older health maintenance organization members: a 2-year randomized trial of the cooperative health care clinic</article-title><source>J Am Geriatr Soc</source><year>2004</year><volume>52</volume><issue>9</issue><fpage>1463</fpage><lpage>1470</lpage><pub-id pub-id-type="pmid">15341547</pub-id></element-citation></ref><ref id="b32-ppa-8-1185"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wermeille</surname><given-names>J</given-names></name><name><surname>Bennie</surname><given-names>M</given-names></name><name><surname>Brown</surname><given-names>I</given-names></name><name><surname>McKnight</surname><given-names>J</given-names></name></person-group><article-title>Pharmaceutical care model for patients with type 2 diabetes: integration of the community pharmacist into the diabetes team &#x02013; a pilot study</article-title><source>Pharm World Sci</source><year>2004</year><volume>26</volume><issue>1</issue><fpage>18</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">15018255</pub-id></element-citation></ref><ref id="b33-ppa-8-1185"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krass</surname><given-names>I</given-names></name><name><surname>Armour</surname><given-names>CL</given-names></name><name><surname>Mitchell</surname><given-names>B</given-names></name><etal/></person-group><article-title>The Pharmacy Diabetes Care Program: assessment of a community pharmacy diabetes service model in Australia</article-title><source>Diabet Med</source><year>2007</year><volume>24</volume><issue>6</issue><fpage>677</fpage><lpage>683</lpage><pub-id pub-id-type="pmid">17523968</pub-id></element-citation></ref><ref id="b34-ppa-8-1185"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krass</surname><given-names>I</given-names></name><name><surname>Mitchell</surname><given-names>B</given-names></name><name><surname>Song</surname><given-names>YJ</given-names></name><etal/></person-group><article-title>Diabetes Medication Assistance Service Stage 1: impact and sustainability of glycaemic and lipids control in patients with Type 2 diabetes</article-title><source>Diabet Med</source><year>2011</year><volume>28</volume><issue>8</issue><fpage>987</fpage><lpage>993</lpage><pub-id pub-id-type="pmid">21418096</pub-id></element-citation></ref><ref id="b35-ppa-8-1185"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Qazaz</surname><given-names>HK</given-names></name><name><surname>Hassali</surname><given-names>MA</given-names></name><name><surname>Shafie</surname><given-names>AA</given-names></name><name><surname>Syed Sulaiman</surname><given-names>SA</given-names></name><name><surname>Sundram</surname><given-names>S</given-names></name></person-group><article-title>Perception and knowledge of patients with type 2 diabetes in Malaysia about their disease and medication: a qualitative study</article-title><source>Res Social Adm Pharm</source><year>2011</year><volume>7</volume><issue>2</issue><fpage>180</fpage><lpage>191</lpage><pub-id pub-id-type="pmid">21272545</pub-id></element-citation></ref><ref id="b36-ppa-8-1185"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chua</surname><given-names>SS</given-names></name><name><surname>Lai</surname><given-names>PSM</given-names></name><name><surname>Tan</surname><given-names>CH</given-names></name><name><surname>Chan</surname><given-names>SP</given-names></name><name><surname>Chung</surname><given-names>WW</given-names></name><name><surname>Morisky</surname><given-names>DE</given-names></name></person-group><article-title>The development and validation of the Malaysian medication adherence scale (MALMAS) among patients with 2 type diabetes in Malaysia</article-title><source>Int J Pharm Pharm Sci</source><year>2013</year><volume>5</volume><issue>3</issue><fpage>790</fpage><lpage>794</lpage><comment>Available from <ext-link ext-link-type="uri" xlink:href="http://www.ijppsjournal.com/Vol5Issue3/7175.pdf">http://www.ijppsjournal.com/Vol5Issue3/7175.pdf</ext-link>. Accessed August 11, 2014.</comment></element-citation></ref><ref id="b37-ppa-8-1185"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morisky</surname><given-names>DE</given-names></name><name><surname>Ang</surname><given-names>A</given-names></name><name><surname>Krousel-Wood</surname><given-names>M</given-names></name><name><surname>Ward</surname><given-names>HJ</given-names></name></person-group><article-title>Predictive validity of a medication adherence measure in an outpatient setting</article-title><source>J Clin Hypertens (Greenwich)</source><year>2008</year><volume>10</volume><issue>5</issue><fpage>348</fpage><lpage>354</lpage><pub-id pub-id-type="pmid">18453793</pub-id></element-citation></ref><ref id="b38-ppa-8-1185"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>S&#x000f6;derg&#x000e5;rd</surname><given-names>B</given-names></name><name><surname>Halvarsson</surname><given-names>M</given-names></name><name><surname>Tully</surname><given-names>MP</given-names></name><etal/></person-group><article-title>Adherence to treatment in Swedish HIV-infected patients</article-title><source>J Clin Pharm Ther</source><year>2006</year><volume>31</volume><issue>6</issue><fpage>605</fpage><lpage>616</lpage><pub-id pub-id-type="pmid">17176366</pub-id></element-citation></ref><ref id="b39-ppa-8-1185"><label>39</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>Centers for Disease Control and Prevention</collab></person-group><year>2011</year><source>National Diabetes Fact Sheet</source><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/diabetes/pubs/fact-sheet11.htm">http://www.cdc.gov/diabetes/pubs/fact-sheet11.htm</ext-link></comment><date-in-citation>Accessed June 24, 2013</date-in-citation></element-citation></ref><ref id="b40-ppa-8-1185"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stratton</surname><given-names>IM</given-names></name><name><surname>Adler</surname><given-names>AI</given-names></name><name><surname>Neil</surname><given-names>HA</given-names></name><etal/></person-group><article-title>Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study</article-title><source>BMJ</source><year>2000</year><volume>321</volume><issue>7258</issue><fpage>405</fpage><lpage>412</lpage><pub-id pub-id-type="pmid">10938048</pub-id></element-citation></ref><ref id="b41-ppa-8-1185"><label>41</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>Jabatan Perangkaan Malaysia</collab></person-group><source>Findings of the Household Income Survey (HIS) 2012</source><year>2012</year><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.statistics.gov.my/portal/images/stories/files/LatestReleases/household/HIS_2012_Eng.pdf">http://www.statistics.gov.my/portal/images/stories/files/LatestReleases/household/HIS_2012_Eng.pdf</ext-link></comment><date-in-citation>Accessed May 20, 2014</date-in-citation></element-citation></ref><ref id="b42-ppa-8-1185"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Expert Consultation WHO</collab><collab>WHO Expert Consultation</collab></person-group><article-title>Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies</article-title><source>Lancet</source><year>2004</year><volume>363</volume><issue>9403</issue><fpage>157</fpage><lpage>163</lpage><pub-id pub-id-type="pmid">14726171</pub-id></element-citation></ref><ref id="b43-ppa-8-1185"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mafauzy</surname><given-names>M</given-names></name><name><surname>Hussein</surname><given-names>Z</given-names></name><name><surname>Chan</surname><given-names>SP</given-names></name></person-group><article-title>The status of diabetes control in Malaysia: results of DiabCare 2008</article-title><source>Med J Malaysia</source><year>2011</year><volume>66</volume><issue>3</issue><fpage>175</fpage><lpage>181</lpage><pub-id pub-id-type="pmid">22111435</pub-id></element-citation></ref><ref id="b44-ppa-8-1185"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hossain</surname><given-names>P</given-names></name><name><surname>Kawar</surname><given-names>B</given-names></name><name><surname>El Nahas</surname><given-names>M</given-names></name></person-group><article-title>Obesity and diabetes in the developing world &#x02013; a growing challenge</article-title><source>N Engl J Med</source><year>2007</year><volume>356</volume><issue>3</issue><fpage>213</fpage><lpage>215</lpage><pub-id pub-id-type="pmid">17229948</pub-id></element-citation></ref><ref id="b45-ppa-8-1185"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>J</given-names></name><name><surname>Sklar</surname><given-names>GE</given-names></name><name><surname>Min Sen Oh</surname><given-names>V</given-names></name><name><surname>Chuen Li</surname><given-names>S</given-names></name></person-group><article-title>Factors affecting therapeutic compliance: A review from the patient&#x02019;s perspective</article-title><source>Ther Clin Risk Manag</source><year>2008</year><volume>4</volume><issue>1</issue><fpage>269</fpage><lpage>286</lpage><pub-id pub-id-type="pmid">18728716</pub-id></element-citation></ref><ref id="b46-ppa-8-1185"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rhee</surname><given-names>MK</given-names></name><name><surname>Slocum</surname><given-names>W</given-names></name><name><surname>Ziemer</surname><given-names>DC</given-names></name><etal/></person-group><article-title>Patient adherence improves glycemic control</article-title><source>Diabetes Educ</source><year>2005</year><volume>31</volume><issue>2</issue><fpage>240</fpage><lpage>250</lpage><pub-id pub-id-type="pmid">15797853</pub-id></element-citation></ref><ref id="b47-ppa-8-1185"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Qazaz</surname><given-names>HK</given-names></name><name><surname>Sulaiman</surname><given-names>SA</given-names></name><name><surname>Hassali</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Diabetes knowledge, medication adherence and glycemic control among patients with type 2 diabetes</article-title><source>Int J Clin Pharmacol</source><year>2011</year><volume>33</volume><issue>6</issue><fpage>1028</fpage><lpage>1035</lpage></element-citation></ref><ref id="b48-ppa-8-1185"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayberry</surname><given-names>LS</given-names></name><name><surname>Osborn</surname><given-names>CY</given-names></name></person-group><article-title>Family support, medication adherence, and glycemic control among adults with type 2 diabetes</article-title><source>Diabetes Care</source><year>2012</year><volume>35</volume><issue>6</issue><fpage>1239</fpage><lpage>1245</lpage><pub-id pub-id-type="pmid">22538012</pub-id></element-citation></ref><ref id="b49-ppa-8-1185"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rausch</surname><given-names>JR</given-names></name><name><surname>Hood</surname><given-names>KK</given-names></name><name><surname>Delamater</surname><given-names>A</given-names></name><etal/></person-group><article-title>Changes in treatment adherence and glycemic control during the transition to adolescence in type 1 diabetes</article-title><source>Diabetes Care</source><year>2012</year><volume>35</volume><issue>6</issue><fpage>1219</fpage><lpage>1224</lpage><pub-id pub-id-type="pmid">22474040</pub-id></element-citation></ref><ref id="b50-ppa-8-1185"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>FB</given-names></name><name><surname>Manson</surname><given-names>JE</given-names></name><name><surname>Stampfer</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Diet, lifestyle, and the risk of type 2 diabetes mellitus in women</article-title><source>N Engl J Med</source><year>2001</year><volume>345</volume><issue>11</issue><fpage>790</fpage><lpage>797</lpage><pub-id pub-id-type="pmid">11556298</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-ppa-8-1185" position="float"><label>Figure 1</label><caption><p>Comparison of FBG between control and intervention groups over time (shown as median in the graph).</p><p><bold>Notes:</bold>
<italic>z</italic>-value, Mann&#x02013;Whitney <italic>U</italic>-test, *statistically significant at <italic>P</italic>&#x0003c;0.05; **<italic>P</italic>&#x0003c;0.01.</p><p><bold>Abbreviations:</bold> FBG, fasting blood glucose; C, control group; I, intervention group; n, number of participants in each group.</p></caption><graphic xlink:href="ppa-8-1185Fig1"/></fig><fig id="f2-ppa-8-1185" position="float"><label>Figure 2</label><caption><p>Comparison of HbA<sub>1c</sub> values between control and intervention groups over time (shown as median in the graph).</p><p><bold>Notes:</bold>
<italic>z</italic>-value, Mann&#x02013;Whitney <italic>U</italic>-test, *statistically significant at <italic>P</italic>&#x0003c;0.05; **<italic>P</italic>&#x0003c;0.01.</p><p><bold>Abbreviations:</bold> HbA<sub>1c</sub>, glycated hemoglobin; C, control group; I, intervention group; n, number of participants in each group.</p></caption><graphic xlink:href="ppa-8-1185Fig2"/></fig><table-wrap id="t1-ppa-8-1185" position="float"><label>Table 1</label><caption><p>Characteristics of participants</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="2" colspan="1">Demographic data<break/>(N=241)</th><th colspan="2" align="left" valign="top" rowspan="1">Frequency (%)
<hr/></th><th align="left" valign="top" rowspan="2" colspan="1"><italic>&#x003c7;</italic><sup>2</sup> (<italic>P</italic>-value)</th><th align="left" valign="top" rowspan="2" colspan="1"><italic>z</italic> value<xref ref-type="table-fn" rid="tfn1-ppa-8-1185">#</xref> (<italic>P</italic>-value)</th></tr><tr><th align="left" valign="top" rowspan="1" colspan="1">Control<break/>(n=121)</th><th align="left" valign="top" rowspan="1" colspan="1">Intervention<break/>(n=120)</th></tr></thead><tbody><tr><td colspan="5" align="left" valign="top" rowspan="1">Sex</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Male</td><td align="left" valign="top" rowspan="1" colspan="1">56 (46.3%)</td><td align="left" valign="top" rowspan="1" colspan="1">50 (41.7%)</td><td align="left" valign="top" rowspan="1" colspan="1">0.521 (0.471)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Female</td><td align="left" valign="top" rowspan="1" colspan="1">65 (53.7%)</td><td align="left" valign="top" rowspan="1" colspan="1">70 (58.3%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age in years, mean &#x000b1; SD (median)</td><td align="left" valign="top" rowspan="1" colspan="1">58.5&#x000b1;8.3 (59.0)</td><td align="left" valign="top" rowspan="1" colspan="1">59.7&#x000b1;9.5 (59.5)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;1.132 (0.258)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;21&#x02013;50</td><td align="left" valign="top" rowspan="1" colspan="1">20 (16.5%)</td><td align="left" valign="top" rowspan="1" colspan="1">17 (14.2%)</td><td align="left" valign="top" rowspan="1" colspan="1">1.505 (0.471)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;51&#x02013;60</td><td align="left" valign="top" rowspan="1" colspan="1">53 (43.8%)</td><td align="left" valign="top" rowspan="1" colspan="1">46 (38.3%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;61&#x02013;75</td><td align="left" valign="top" rowspan="1" colspan="1">48 (39.7%)</td><td align="left" valign="top" rowspan="1" colspan="1">57 (47.5%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">Ethnic group</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Malay</td><td align="left" valign="top" rowspan="1" colspan="1">47 (38.8%)</td><td align="left" valign="top" rowspan="1" colspan="1">61 (50.8%)</td><td align="left" valign="top" rowspan="1" colspan="1">4.830 (0.089)<xref ref-type="table-fn" rid="tfn2-ppa-8-1185">@</xref></td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Chinese</td><td align="left" valign="top" rowspan="1" colspan="1">23 (19.0%)</td><td align="left" valign="top" rowspan="1" colspan="1">26 (21.7%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Indian</td><td align="left" valign="top" rowspan="1" colspan="1">47 (38.8%)</td><td align="left" valign="top" rowspan="1" colspan="1">32 (26.7%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Others</td><td align="left" valign="top" rowspan="1" colspan="1">4 (3.3%)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (0.8%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">Marital Status</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Single</td><td align="left" valign="top" rowspan="1" colspan="1">4 (3.3%)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (3.3%)</td><td align="left" valign="top" rowspan="1" colspan="1">3.089 (0.378)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Married</td><td align="left" valign="top" rowspan="1" colspan="1">97 (80.2%)</td><td align="left" valign="top" rowspan="1" colspan="1">98 (81.7%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Divorced</td><td align="left" valign="top" rowspan="1" colspan="1">7 (5.8%)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (1.7%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Widower</td><td align="left" valign="top" rowspan="1" colspan="1">13 (10.7%)</td><td align="left" valign="top" rowspan="1" colspan="1">16 (13.3%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">Level of education</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;None and primary</td><td align="left" valign="top" rowspan="1" colspan="1">13 (10.7%)</td><td align="left" valign="top" rowspan="1" colspan="1">8 (6.7%)</td><td align="left" valign="top" rowspan="1" colspan="1">6.637 (0.084)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Secondary</td><td align="left" valign="top" rowspan="1" colspan="1">75 (62.0%)</td><td align="left" valign="top" rowspan="1" colspan="1">61 (50.8%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Diploma</td><td align="left" valign="top" rowspan="1" colspan="1">16 (13.2%)</td><td align="left" valign="top" rowspan="1" colspan="1">27 (22.5%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Tertiary and postgraduate</td><td align="left" valign="top" rowspan="1" colspan="1">17 (14.0%)</td><td align="left" valign="top" rowspan="1" colspan="1">24 (20.0%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">Working status</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Yes</td><td align="left" valign="top" rowspan="1" colspan="1">50 (41.3%)</td><td align="left" valign="top" rowspan="1" colspan="1">48 (40.0%)</td><td align="left" valign="top" rowspan="1" colspan="1">0.044 (0.834)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;No</td><td align="left" valign="top" rowspan="1" colspan="1">71 (58.7%)</td><td align="left" valign="top" rowspan="1" colspan="1">72 (60.0%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">Income per month</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02264; RM1,000 (USD$309)</td><td align="left" valign="top" rowspan="1" colspan="1">48 (39.7%)</td><td align="left" valign="top" rowspan="1" colspan="1">49 (40.8%)</td><td align="left" valign="top" rowspan="1" colspan="1">6.826 (0.234)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;RM1,001&#x02013;3,000 (USD$310&#x02013;$929)</td><td align="left" valign="top" rowspan="1" colspan="1">45 (37.2%)</td><td align="left" valign="top" rowspan="1" colspan="1">47 (39.2%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;RM3,001&#x02013;5,000 (USD$930&#x02013;$1,548)</td><td align="left" valign="top" rowspan="1" colspan="1">24 (19.8%)</td><td align="left" valign="top" rowspan="1" colspan="1">14 (11.7%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02265; RM5,001 (USD$1,549)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (3.3%)</td><td align="left" valign="top" rowspan="1" colspan="1">10 (8.3%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Body mass index in kg/m<sup>2</sup><xref ref-type="table-fn" rid="tfn3-ppa-8-1185">@@</xref>, mean &#x000b1; SD (median)</td><td align="left" valign="top" rowspan="1" colspan="1">29.1&#x000b1;7.0 (28.4)</td><td align="left" valign="top" rowspan="1" colspan="1">29.3&#x000b1;6.3 (28.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.288 (0.773)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Underweight to healthy weight</td><td align="left" valign="top" rowspan="1" colspan="1">27 (23.5)</td><td align="left" valign="top" rowspan="1" colspan="1">21 (18.4)</td><td align="left" valign="top" rowspan="1" colspan="1">1.917 (0.383)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Overweight</td><td align="left" valign="top" rowspan="1" colspan="1">44 (38.3)</td><td align="left" valign="top" rowspan="1" colspan="1">58 (50.9)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Obese</td><td align="left" valign="top" rowspan="1" colspan="1">44 (38.3)</td><td align="left" valign="top" rowspan="1" colspan="1">35 (30.7)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">Number of times patient exercises in a week</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02264; Once a week</td><td align="left" valign="top" rowspan="1" colspan="1">43 (35.5%)</td><td align="left" valign="top" rowspan="1" colspan="1">35 (29.2%)</td><td align="left" valign="top" rowspan="1" colspan="1">2.208 (0.331)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Twice a week</td><td align="left" valign="top" rowspan="1" colspan="1">10 (8.3%)</td><td align="left" valign="top" rowspan="1" colspan="1">16 (13.3%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02265; Three times a week</td><td align="left" valign="top" rowspan="1" colspan="1">68 (56.2%)</td><td align="left" valign="top" rowspan="1" colspan="1">69 (57.5%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Duration of diabetes in years, mean &#x000b1; SD (median)</td><td align="left" valign="top" rowspan="1" colspan="1">16.3&#x000b1;8.0 (15.0)</td><td align="left" valign="top" rowspan="1" colspan="1">16.3&#x000b1;8.0 (15.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.112 (0.911)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;0&#x02013;10 years</td><td align="left" valign="top" rowspan="1" colspan="1">28 (23.1%)</td><td align="left" valign="top" rowspan="1" colspan="1">30 (25.0%)</td><td align="left" valign="top" rowspan="1" colspan="1">0.623 (0.732)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;11&#x02013;20 years</td><td align="left" valign="top" rowspan="1" colspan="1">52 (43.0%)</td><td align="left" valign="top" rowspan="1" colspan="1">55 (45.8%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x0003e;20 years</td><td align="left" valign="top" rowspan="1" colspan="1">41 (33.9%)</td><td align="left" valign="top" rowspan="1" colspan="1">35 (29.2%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">Number of concurrent diseases</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;0</td><td align="left" valign="top" rowspan="1" colspan="1">38 (31.4%)</td><td align="left" valign="top" rowspan="1" colspan="1">30 (25.0%)</td><td align="left" valign="top" rowspan="1" colspan="1">2.578 (0.765)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;1</td><td align="left" valign="top" rowspan="1" colspan="1">31 (25.6%)</td><td align="left" valign="top" rowspan="1" colspan="1">41 (34.2%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;2</td><td align="left" valign="top" rowspan="1" colspan="1">34 (28.1%)</td><td align="left" valign="top" rowspan="1" colspan="1">33 (29.5%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x0003e;3</td><td align="left" valign="top" rowspan="1" colspan="1">18 (14.9%)</td><td align="left" valign="top" rowspan="1" colspan="1">16 (13.3%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Number of prescribed medications, mean &#x000b1; SD (median)</td><td align="left" valign="top" rowspan="1" colspan="1">6.1&#x000b1;2.2 (6.0)</td><td align="left" valign="top" rowspan="1" colspan="1">6.4&#x000b1;2.1 (6.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.247 (0.805)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;0&#x02013;5 types</td><td align="left" valign="top" rowspan="1" colspan="1">47 (38.8%)</td><td align="left" valign="top" rowspan="1" colspan="1">41 (34.2%)</td><td align="left" valign="top" rowspan="1" colspan="1">0.568 (0.451)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02265;6 types</td><td align="left" valign="top" rowspan="1" colspan="1">74 (61.2%)</td><td align="left" valign="top" rowspan="1" colspan="1">79 (65.8%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">Medications prescribed at baseline</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Alpha-glucosidase inhibitor</td><td align="left" valign="top" rowspan="1" colspan="1">9 (3.5%)</td><td align="left" valign="top" rowspan="1" colspan="1">17 (6.7%)</td><td align="left" valign="top" rowspan="1" colspan="1">0.287<xref ref-type="table-fn" rid="tfn4-ppa-8-1185">^</xref> (0.866)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Biguanide</td><td align="left" valign="top" rowspan="1" colspan="1">108 (41.9%)</td><td align="left" valign="top" rowspan="1" colspan="1">105 (41.2%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Dipeptidyl peptidase-4 inihibitor</td><td align="left" valign="top" rowspan="1" colspan="1">2 (0.8%)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Meglitinide</td><td align="left" valign="top" rowspan="1" colspan="1">1 (0.4%)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">Medications prescribed at baseline</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Sulphonylurea</td><td align="left" valign="top" rowspan="1" colspan="1">39 (15.1%)</td><td align="left" valign="top" rowspan="1" colspan="1">36 (14.1%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Thiazolidinedione</td><td align="left" valign="top" rowspan="1" colspan="1">3 (1.2%)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (0.8%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Insulin</td><td align="left" valign="top" rowspan="1" colspan="1">96 (37.2%)</td><td align="left" valign="top" rowspan="1" colspan="1">95 (37.3%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Incretin mimetic</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0%)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">Medications prescribed at the twelfth month</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Alpha-glucosidase inhibitor</td><td align="left" valign="top" rowspan="1" colspan="1">3 (1.2%)</td><td align="left" valign="top" rowspan="1" colspan="1">11 (4.5%)</td><td align="left" valign="top" rowspan="1" colspan="1">2.024<xref ref-type="table-fn" rid="tfn4-ppa-8-1185">^</xref> (0.567)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Biguanide</td><td align="left" valign="top" rowspan="1" colspan="1">103 (41.9%)</td><td align="left" valign="top" rowspan="1" colspan="1">94 (38.5%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Dipeptidyl peptidase-4 inhibitor</td><td align="left" valign="top" rowspan="1" colspan="1">6 (2.4%)</td><td align="left" valign="top" rowspan="1" colspan="1">7 (2.9%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Meglitinide</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0%)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0%0</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Sulphonylurea</td><td align="left" valign="top" rowspan="1" colspan="1">32 (13.0%)</td><td align="left" valign="top" rowspan="1" colspan="1">35 (14.3%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Thiazolidinedione</td><td align="left" valign="top" rowspan="1" colspan="1">1 (0.4%)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Insulin</td><td align="left" valign="top" rowspan="1" colspan="1">100 (40.7%)</td><td align="left" valign="top" rowspan="1" colspan="1">95 (38.9%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Incretin mimetic</td><td align="left" valign="top" rowspan="1" colspan="1">1 (0.4%)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (0.8%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p><bold>Notes:</bold></p></fn><fn id="tfn1-ppa-8-1185"><label>#</label><p>Mann&#x02013;Whitney <italic>U</italic>-test is used for continuous variables; <italic>&#x003c7;</italic><sup>2</sup>, chi-square test used for categorical variables</p></fn><fn id="tfn2-ppa-8-1185"><label>@</label><p>chi-square value was obtained by omitting the ethnic group &#x0201c;Others&#x0201d;</p></fn><fn id="tfn3-ppa-8-1185"><label>@@</label><p>healthy weight range, 18.5&#x02013;24.9 kg/m<sup>2</sup>; overweight, 25&#x02013;29.9 kg/m<sup>2</sup>; obese, &#x02265;30 kg/m<sup>2</sup></p></fn><fn id="tfn4-ppa-8-1185"><label>^</label><p>chi-square value was obtained by analyzing the major classes of antidiabetes agents (biguanide, sulfonylurea, and insulin), as the sample size for the other classes was very small.</p></fn><fn id="tfn5-ppa-8-1185"><p><bold>Abbreviation:</bold> N, total participants in the study; n, number of participants in each group; SD, standard deviation.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-ppa-8-1185" position="float"><label>Table 2</label><caption><p>Comparison of medication adherence between control and intervention groups based on three levels of adherence</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="2" colspan="1">Medication adherence</th><th colspan="2" align="left" valign="top" rowspan="1">Frequency (%)
<hr/></th><th align="left" valign="top" rowspan="2" colspan="1"><italic>&#x003c7;</italic><sup>2</sup> (<italic>P</italic>-value)</th></tr><tr><th align="left" valign="top" rowspan="1" colspan="1">Control</th><th align="left" valign="top" rowspan="1" colspan="1">Intervention</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Baseline</td><td align="left" valign="top" rowspan="1" colspan="1">n=121</td><td align="left" valign="top" rowspan="1" colspan="1">n=120</td><td align="left" valign="top" rowspan="1" colspan="1">1.900 (0.387)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Low adherence</td><td align="left" valign="top" rowspan="1" colspan="1">43 (35.5%)</td><td align="left" valign="top" rowspan="1" colspan="1">36 (30.0%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Medium adherence</td><td align="left" valign="top" rowspan="1" colspan="1">43 (35.5%)</td><td align="left" valign="top" rowspan="1" colspan="1">53 (44.2%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;High adherence</td><td align="left" valign="top" rowspan="1" colspan="1">35 (28.9%)</td><td align="left" valign="top" rowspan="1" colspan="1">31 (25.8%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Month 4</td><td align="left" valign="top" rowspan="1" colspan="1">n=109</td><td align="left" valign="top" rowspan="1" colspan="1">n=115</td><td align="left" valign="top" rowspan="1" colspan="1">7.310 (0.026)<xref ref-type="table-fn" rid="tfn6-ppa-8-1185">*</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Low adherence</td><td align="left" valign="top" rowspan="1" colspan="1">48 (44.0%)</td><td align="left" valign="top" rowspan="1" colspan="1">31 (27.0%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Medium adherence</td><td align="left" valign="top" rowspan="1" colspan="1">35 (32.1%)</td><td align="left" valign="top" rowspan="1" colspan="1">52 (44.3%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;High adherence</td><td align="left" valign="top" rowspan="1" colspan="1">26 (23.9%)</td><td align="left" valign="top" rowspan="1" colspan="1">33 (28.7%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Month 8</td><td align="left" valign="top" rowspan="1" colspan="1">n=110</td><td align="left" valign="top" rowspan="1" colspan="1">n=102</td><td align="left" valign="top" rowspan="1" colspan="1">7.289 (0.026)<xref ref-type="table-fn" rid="tfn6-ppa-8-1185">*</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Low adherence</td><td align="left" valign="top" rowspan="1" colspan="1">46 (41.8%)</td><td align="left" valign="top" rowspan="1" colspan="1">25 (24.5%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Medium adherence</td><td align="left" valign="top" rowspan="1" colspan="1">33 (30.0%)</td><td align="left" valign="top" rowspan="1" colspan="1">37 (36.3%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;High adherence</td><td align="left" valign="top" rowspan="1" colspan="1">31 (28.2%)</td><td align="left" valign="top" rowspan="1" colspan="1">40 (39.2%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Month 12</td><td align="left" valign="top" rowspan="1" colspan="1">n=121</td><td align="left" valign="top" rowspan="1" colspan="1">n=120</td><td align="left" valign="top" rowspan="1" colspan="1">8.182 (0.017)<xref ref-type="table-fn" rid="tfn6-ppa-8-1185">*</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Low adherence</td><td align="left" valign="top" rowspan="1" colspan="1">50 (41.3%)</td><td align="left" valign="top" rowspan="1" colspan="1">30 (25.0%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Medium adherence</td><td align="left" valign="top" rowspan="1" colspan="1">41 (33.9%)</td><td align="left" valign="top" rowspan="1" colspan="1">45 (37.5%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;High adherence</td><td align="left" valign="top" rowspan="1" colspan="1">30 (24.8%)</td><td align="left" valign="top" rowspan="1" colspan="1">45 (37.5%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p><bold>Notes:</bold></p></fn><fn id="tfn6-ppa-8-1185"><label>*</label><p>Statistically significant at <italic>P</italic>&#x0003c;0.05. <italic>&#x003c7;</italic><sup>2</sup>, chi-square test.</p></fn><fn id="tfn7-ppa-8-1185"><p><bold>Abbreviations:</bold> n, total number of participants in each group.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3-ppa-8-1185" position="float"><label>Table 3</label><caption><p>Comparison of medication adherence between control and intervention groups when classified as nonadherence and adherence</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="2" colspan="1">Adherence/nonadherence</th><th colspan="2" align="left" valign="top" rowspan="1">Frequency (%)
<hr/></th><th align="left" valign="top" rowspan="2" colspan="1"><italic>&#x003c7;</italic><sup>2</sup> (<italic>P</italic>-value)</th></tr><tr><th align="left" valign="top" rowspan="1" colspan="1">Control</th><th align="left" valign="top" rowspan="1" colspan="1">Intervention</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Baseline</td><td align="left" valign="top" rowspan="1" colspan="1">n=121</td><td align="left" valign="top" rowspan="1" colspan="1">n=120</td><td align="left" valign="top" rowspan="1" colspan="1">0.838 (0.360)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Nonadherence</td><td align="left" valign="top" rowspan="1" colspan="1">43 (35.0%)</td><td align="left" valign="top" rowspan="1" colspan="1">36 (30.0%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Adherence</td><td align="left" valign="top" rowspan="1" colspan="1">78 (64.5%)</td><td align="left" valign="top" rowspan="1" colspan="1">84 (70.0%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Month 4</td><td align="left" valign="top" rowspan="1" colspan="1">n=109</td><td align="left" valign="top" rowspan="1" colspan="1">n=115</td><td align="left" valign="top" rowspan="1" colspan="1">7.151 (0.007)<xref ref-type="table-fn" rid="tfn9-ppa-8-1185">*</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Nonadherence</td><td align="left" valign="top" rowspan="1" colspan="1">48 (44.0%)</td><td align="left" valign="top" rowspan="1" colspan="1">31 (27.0%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Adherence</td><td align="left" valign="top" rowspan="1" colspan="1">61 (56.0%)</td><td align="left" valign="top" rowspan="1" colspan="1">84 (73.0%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Month 8</td><td align="left" valign="top" rowspan="1" colspan="1">n=110</td><td align="left" valign="top" rowspan="1" colspan="1">n=102</td><td align="left" valign="top" rowspan="1" colspan="1">7.118 (0.008)<xref ref-type="table-fn" rid="tfn9-ppa-8-1185">*</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Nonadherence</td><td align="left" valign="top" rowspan="1" colspan="1">46 (41.8%)</td><td align="left" valign="top" rowspan="1" colspan="1">25 (24.5%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Adherence</td><td align="left" valign="top" rowspan="1" colspan="1">64 (58.2%)</td><td align="left" valign="top" rowspan="1" colspan="1">77 (75.5%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Month 12</td><td align="left" valign="top" rowspan="1" colspan="1">n=121</td><td align="left" valign="top" rowspan="1" colspan="1">n=120</td><td align="left" valign="top" rowspan="1" colspan="1">7.238 (0.007)<xref ref-type="table-fn" rid="tfn9-ppa-8-1185">*</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Nonadherence</td><td align="left" valign="top" rowspan="1" colspan="1">50 (41.3%)</td><td align="left" valign="top" rowspan="1" colspan="1">30 (25.0%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Adherence</td><td align="left" valign="top" rowspan="1" colspan="1">71 (58.7%)</td><td align="left" valign="top" rowspan="1" colspan="1">90 (75.0%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tfn8-ppa-8-1185"><p><bold>Notes:</bold>
<italic>&#x003c7;</italic><sup>2</sup>, chi-square test,</p></fn><fn id="tfn9-ppa-8-1185"><label>*</label><p>statistically significant at <italic>P</italic>&#x0003c;0.01.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t4-ppa-8-1185" position="float"><label>Table 4</label><caption><p>Comparison of fasting blood glucose and glycated hemoglobin (HbA<sub>1c</sub>) within control and intervention groups over the study period</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="2" colspan="1">Differences</th><th colspan="2" align="left" valign="top" rowspan="1">Fasting blood glucose (<italic>z</italic>-value <xref ref-type="table-fn" rid="tfn10-ppa-8-1185">#</xref> [<italic>P</italic>-value])
<hr/></th><th colspan="2" align="left" valign="top" rowspan="1">HbA<sub>1c</sub> (<italic>z</italic>-value<xref ref-type="table-fn" rid="tfn10-ppa-8-1185">#</xref> [<italic>P</italic>-value])
<hr/></th></tr><tr><th align="left" valign="top" rowspan="1" colspan="1">Control</th><th align="left" valign="top" rowspan="1" colspan="1">Intervention</th><th align="left" valign="top" rowspan="1" colspan="1">Control</th><th align="left" valign="top" rowspan="1" colspan="1">Intervention</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Baseline&#x02013;4 months</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.761 (0.446)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;3.968 (&#x0003c;0.001)<xref ref-type="table-fn" rid="tfn11-ppa-8-1185">*</xref></td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;1.780 (0.075)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;8.595 (&#x0003c;0.001)<xref ref-type="table-fn" rid="tfn11-ppa-8-1185">*</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Baseline&#x02013;8 months</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;1.451 (0.147)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;2.784 (0.005)<xref ref-type="table-fn" rid="tfn11-ppa-8-1185">*</xref></td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.831 (0.406)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;7.157 (&#x0003c;0.001)<xref ref-type="table-fn" rid="tfn11-ppa-8-1185">*</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Baseline&#x02013;12 months</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;1.134 (0.257)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;5.909 (&#x0003c;0.001)<xref ref-type="table-fn" rid="tfn11-ppa-8-1185">*</xref></td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;1.115 (0.265)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;8.265 (&#x0003c;0.001)<xref ref-type="table-fn" rid="tfn11-ppa-8-1185">*</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">4 months&#x02013;8 months</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.109 (0.913)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.511 (0.609)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.823 (0.411)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;2.728 (0.006)<xref ref-type="table-fn" rid="tfn11-ppa-8-1185">*</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">4 months&#x02013;12 months</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.008 (0.994)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;2.980 (0.003)<xref ref-type="table-fn" rid="tfn11-ppa-8-1185">*</xref></td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.554 (0.580)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;4.831 (&#x0003c;0.001)<xref ref-type="table-fn" rid="tfn11-ppa-8-1185">*</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">8 months&#x02013;12 months</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.268 (0.788)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;3.264 (0.001)<xref ref-type="table-fn" rid="tfn11-ppa-8-1185">*</xref></td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.159 (0.874)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;4.884 (&#x0003c;0.001)<xref ref-type="table-fn" rid="tfn11-ppa-8-1185">*</xref></td></tr></tbody></table><table-wrap-foot><fn><p><bold>Notes:</bold></p></fn><fn id="tfn10-ppa-8-1185"><label>#</label><p><italic>z</italic>-value, Wilcoxon signed-rank test</p></fn><fn id="tfn11-ppa-8-1185"><label>*</label><p>statistically significant at <italic>P</italic>&#x0003c;0.01.</p></fn><fn id="tfn12-ppa-8-1185"><p><bold>Abbreviation:</bold> HbA<sub>1c</sub>, glycated hemoglobin.</p></fn></table-wrap-foot></table-wrap></floats-group></article>